Tadalafil Ratiopharm 5 mg tabletti, kalvopäällysteinen Finlandia - Suomi - Fimea (Suomen lääkevirasto)

tadalafil ratiopharm 5 mg tabletti, kalvopäällysteinen

orifarm oy - tadalafil - tabletti, kalvopäällysteinen - 5 mg - tadalafiili

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Uni Eropa - Suomi - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogreelin hydrokloridi - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitromboottiset aineet - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

VENLAFAXIN TAD 37.5 mg depotkapseli, kova Finlandia - Suomi - Fimea (Suomen lääkevirasto)

venlafaxin tad 37.5 mg depotkapseli, kova

tad pharma gmbh - venlafaxini hydrochloridum - depotkapseli, kova - 37.5 mg - venlafaksiini

VENLAFAXIN TAD 75 mg depotkapseli, kova Finlandia - Suomi - Fimea (Suomen lääkevirasto)

venlafaxin tad 75 mg depotkapseli, kova

tad pharma gmbh - venlafaxini hydrochloridum - depotkapseli, kova - 75 mg - venlafaksiini

VENLAFAXIN TAD 150 mg depotkapseli, kova Finlandia - Suomi - Fimea (Suomen lääkevirasto)

venlafaxin tad 150 mg depotkapseli, kova

tad pharma gmbh - venlafaxini hydrochloridum - depotkapseli, kova - 150 mg - venlafaksiini

Amoxicillin Mip Pharma 500 mg tabletti Finlandia - Suomi - Fimea (Suomen lääkevirasto)

amoxicillin mip pharma 500 mg tabletti

mip pharma gmbh - amoxicillin trihydrate - tabletti - 500 mg - amoksisilliini

Buprenorphine/Naloxone G.L. Pharma 2 mg / 0,5 mg resoribletti Finlandia - Suomi - Fimea (Suomen lääkevirasto)

buprenorphine/naloxone g.l. pharma 2 mg / 0,5 mg resoribletti

g.l. pharma gmbh - buprenorphine hydrochloride, naloxone hydrochloride dihydrate - resoribletti - 2 mg / 0,5 mg - buprenorfiini

Buprenorphine/Naloxone G.L. Pharma 4 mg / 1 mg resoribletti Finlandia - Suomi - Fimea (Suomen lääkevirasto)

buprenorphine/naloxone g.l. pharma 4 mg / 1 mg resoribletti

g.l. pharma gmbh - buprenorphine hydrochloride, naloxone hydrochloride dihydrate - resoribletti - 4 mg / 1 mg - buprenorfiini

Buprenorphine/Naloxone G.L. Pharma 8 mg / 2 mg resoribletti Finlandia - Suomi - Fimea (Suomen lääkevirasto)

buprenorphine/naloxone g.l. pharma 8 mg / 2 mg resoribletti

g.l. pharma gmbh - buprenorphine hydrochloride, naloxone hydrochloride dihydrate - resoribletti - 8 mg / 2 mg - buprenorfiini

CARDIOSTAD 2.5 mg tabletti Finlandia - Suomi - Fimea (Suomen lääkevirasto)

cardiostad 2.5 mg tabletti

stada arzneimittel ag - lisinoprilum dihydricum - tabletti - 2.5 mg - lisinopriili